Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase 1a/b Clinical Trial of its Allosteric STING Agonist CRD3874-SI in Patients with Advanced Cancer at Memorial Sloan Kettering Cancer Center in New York
CRD3874-SI is a small molecule drug designed to target the STimulator of INterferon Genes, to activate immune cells to identify
Read More